Clinical trials · New York, NY
Smoldering Multiple Myeloma clinical trials in New York
We’re tracking 17 recruiting smoldering multiple myeloma studies with a site in or near New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT06365060Recruiting
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
This study is screening people with smoldering multiple myeloma or a monoclonal gammopathy to see if they might have an early form of AL amyloidosis, a condition where abnormal proteins build up in organs. If you meet the criteria, you will be tested to find out if you have amyloidosis, which could help catch it early.
New York, New YorkAges 40 years+ - NCT06140524RecruitingPhase 2
Study of Linvoseltamab for high-risk MGUS or smoldering myeloma
This trial tests if linvoseltamab can remove abnormal plasma cells that might turn into multiple myeloma. It is for patients with high-risk MGUS (a precancerous condition) or non-high-risk smoldering myeloma who have not yet developed active myeloma.
New York, New YorkAges 18 years+ - NCT06106945RecruitingPhase 1/Phase 2
AZD0305 alone or with other drugs for multiple myeloma
This trial tests a new drug called AZD0305, either by itself or combined with other cancer drugs, for people with multiple myeloma. It aims to see if the treatment is safe and effective.
New York, New YorkAges 18 years+ - NCT02343042RecruitingPhase 1/Phase 2
Selinexor with standard therapies for multiple myeloma
This trial tests a new drug called selinexor (KPT-330) combined with various standard treatments for patients whose multiple myeloma has come back or stopped responding to therapy. The goal is to see if adding selinexor helps control the cancer better than current options, and to find the safest dose for different drug pairings.
New York, New YorkAges 18 years+ - NCT05623020RecruitingPhase 3
New treatment for newly diagnosed transplant-ineligible myeloma
This Phase 3 study compares a three-drug combination (elranatamab, daratumumab, and lenalidomide) versus a standard three-drug treatment (daratumumab, bortezomib, lenalidomide, plus dexamethasone). It aims to see which plan works better for people newly diagnosed with multiple myeloma who cannot get a stem cell transplant.
New York, New YorkAges 18 years+ - NCT05020236RecruitingPhase 3
Elranatamab with daratumumab for previously treated myeloma
This trial studies elranatamab (alone and combined with daratumumab) in people with multiple myeloma who have already received other treatments, including lenalidomide. It aims to see how well these medicines control the cancer and what side effects people experience.
New York, New YorkAges 18 years+ - NCT07280013RecruitingPhase 1
Cemsidomide with elranatamab for multiple myeloma
This trial tests a new drug combination (cemsidomide and elranatamab) for people with multiple myeloma that has come back after previous treatments. The goal is to see if the combination is safe and works better than current options.
New York, New YorkAges 18 years+ - NCT05640843Recruiting
Plant-based diet study for MGUS or smoldering myeloma
This trial tests whether a whole-food, plant-based eating pattern—plus supplements or placebo—can improve health outcomes in people with MGUS or smoldering multiple myeloma. You may be asked to follow specific recipes and stop certain supplements, so it helps to confirm you can stick with the plan.
New York, New YorkAges 18 years+ - NCT07099391RecruitingPhase 1/Phase 2
Study of two drug combos for newly diagnosed multiple myeloma
This trial tests two combinations of drugs (Dara-RVd and Teclistamab-RVd) for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if adding a newer drug called Teclistamab improves outcomes.
New York, New YorkAges 18 years+ - NCT06679101RecruitingPhase 3
Belantamab combination vs standard care for newly diagnosed multiple myeloma
This trial tests a new drug combination (belantamab mafodotin plus lenalidomide and dexamethasone) against the usual treatment for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. It aims to see if the new combination works better.
New York, New YorkAges 18 years+ - NCT07454382RecruitingPhase 2
Study of elranatamab and cyclophosphamide for multiple myeloma
This trial studies a new medicine called elranatamab combined with the chemotherapy drug cyclophosphamide for people with multiple myeloma that has returned or not responded to prior treatments. It may be a good option if you have aggressive or high-risk myeloma.
New York, New YorkAges 18 years+ - NCT06215118RecruitingPhase 1
Combination therapy for relapsed or refractory multiple myeloma
This trial tests a new combination of two drugs, elranatamab and iberdomide, for people whose multiple myeloma has returned or stopped responding to previous treatments. The goal is to see if this combination can help control the disease.
New York, New YorkAges 18 years+ - NCT07665307Recruiting
Delayed side effects after CAR-T for multiple myeloma
This study looks at late side effects that may happen after CAR-T therapy (cilta-cel) for multiple myeloma. It aims to better understand these delayed toxicities so doctors can manage them more effectively.
New York, New YorkAges 18 years+ - NCT03937635RecruitingPhase 3
Lenalidomide and dexamethasone, with or without daratumumab
This phase 3 trial studies whether lenalidomide plus dexamethasone can prevent or delay progression of “high-risk smoldering” multiple myeloma, and whether adding daratumumab improves outcomes. It’s meant for people who are not yet showing symptoms, but whose lab and scan results suggest higher risk.
New York, New YorkAges 18 years+ - NCT05552222RecruitingPhase 3
New treatment combo study for newly diagnosed multiple myeloma
This phase 3 trial tests two different drug combinations to treat newly diagnosed multiple myeloma. It may help by aiming to control the cancer without using high-dose chemotherapy and stem cell transplant for people who can’t receive that approach.
New York, New YorkAges 18 years+ - NCT06055894Recruiting
Plant-based diet and supplements for smoldering myeloma or MGUS
This study tests whether a plant-based diet and certain supplements can help people with smoldering multiple myeloma (SMM) or monoclonal gammopathy of undetermined significance (MGUS). Participants will learn to cook plant-based recipes and track their meals using a phone app.
New York, New YorkAges 18 years+ - NCT06152575RecruitingPhase 3
Study of elranatamab for multiple myeloma that returned after other treatments
This trial tests a new medicine called elranatamab in people whose multiple myeloma has come back after they tried other treatments, including a specific type of immunotherapy (anti-CD38) and the drug lenalidomide. The goal is to see if this medicine can help control the cancer.
Lake Success, New YorkAges 18 years+
Hear when a new Smoldering Multiple Myeloma trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Smoldering Multiple Myeloma trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting smoldering multiple myeloma studies listed above.
- Memorial Sloan Kettering Cancer Center · 11 studies
- Memorial Sloan Kettering Bergen · 7 studies
- Memorial Sloan Kettering Monmouth · 7 studies
- Memorial Sloan Kettering Nassau · 7 studies
- Memorial Sloan Kettering Cancer Center - Westchester · 6 studies
- Memorial Sloan Kettering Basking Ridge · 4 studies
- Memorial Sloan Kettering Commack · 4 studies
- Columbia University Irving Medical Center · 3 studies
What taking part in a smoldering multiple myeloma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting smoldering multiple myeloma studies in New York.
Common questions
- Are there smoldering multiple myeloma clinical trials near New York?
- Yes. We're currently tracking 17 recruiting smoldering multiple myeloma studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a smoldering multiple myeloma study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a smoldering multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New smoldering multiple myeloma studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.